Roivant Sciences Ltd. (ROIV) — 13F Filings Explorer (Q2 2026)

ROIV ranks #1180 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ROIV is a top-conviction position for QVT Financial LP — at 49.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ROIV belongs to FMR LLC, but the position matters far more to QVT Financial LP, who has 49.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its ROIV position for two straight quarters, increasing it by $1.4B to reach $2.9B today.

Marshall Wace, LLP has trimmed its ROIV position for two straight quarters, cutting it by $24.8M while still holding $50.3M.

ROIV is up 0.8% today, and institutions have been net buyers of $2.5B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ROIV reported a net loss of $266.3M over the trailing twelve months.

• Not yet profitable — net loss of $266.3M over the trailing twelve months
• Revenue declined 67.6% year over year
• Net income improved year over year, from -$490.6M to -$266.3M
• Operating cash flow was negative, using $750.3M in cash
• Current ratio of 18.37x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range